fig2
![Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics](https://image.oaes.cc/464173fe-9566-4a21-9155-9a32e0afc191/3277.fig.2.jpg)
Figure 2. Timeline of rapamycin and rapalogs from discovery to clinic. Rapalogs include temsirolimus, everolimus and ridaforolimus. RCC: renal cell carcinoma; SEGA: subependymal giant cell astrocytoma; BC: breast cancer; PNET: pancreatic neuroendocrine tumours; FDA: Food and Drug Administration (United States of America)